Yahoo Web Search

Search results

  1. Jan 1, 2022 · This study evaluated the therapeutic efficacy of high-dose recombinant human C1 inhibitor (rhC1INH) to prevent DGF in a nonhuman primate model of kidney transplantation after brain death (BD) and prolonged cold ischemia. Methods: BD donors underwent 20-hours of conventional management.

  2. rhC1INH treatment in BD donors improves graft function and reduces kidney injury and incidence of DGF in transplant recipients. (a) Serum creatinine levels in recipients of kidney grafts from donors in G1 (vehicle, n=6), G2 (rhC1INH+ heparin, n=6), and G3 (heparin, n=3).

    • Juan S. Danobeitia, Tiffany J. Zens, Peter J. Chlebeck, Laura J. Zitur, Jose A. Reyes, Michael J. Ee...
    • 10.1111/ajt.15777
    • 2020
    • 2020/06
  3. Delayed graft function (DGF) in renal transplant is associated with reduced graft survival and increased immunogenicity. The complement-driven inflammatory response after brain death (BD) and posttransplant reperfusion injury play significant roles in the pathogenesis of DGF.

    • Juan S. Danobeitia, Tiffany J. Zens, Peter J. Chlebeck, Laura J. Zitur, Jose A. Reyes, Michael J. Ee...
    • 2020
  4. Jan 1, 2022 · Our results recommend high-dose C1INH complement blockade in transplant recipients as an effective strategy to reduce kidney injury and inflammation, prevent DGF, delay antibody-mediated rejection development, and improve transplant outcomes.

  5. www.amjtransplant.org › article › S1600-6135(22www.amjtransplant.org

    Targeted donor complement blockade after brain death prevents delayed graft function in a nonhuman primate model of kidney transplantation

  6. Jeremy M. Sullivan. Johns Hopkins University School of Medicine. Verified email at jhmi.edu. Neuroscience. Articles Cited by Public access. Title. Sort.